| pubmed-article:6393687 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6393687 | lifeskim:mentions | umls-concept:C0392535 | lld:lifeskim |
| pubmed-article:6393687 | lifeskim:mentions | umls-concept:C0012356 | lld:lifeskim |
| pubmed-article:6393687 | lifeskim:mentions | umls-concept:C0007874 | lld:lifeskim |
| pubmed-article:6393687 | lifeskim:mentions | umls-concept:C0442027 | lld:lifeskim |
| pubmed-article:6393687 | lifeskim:mentions | umls-concept:C0012359 | lld:lifeskim |
| pubmed-article:6393687 | lifeskim:mentions | umls-concept:C0012472 | lld:lifeskim |
| pubmed-article:6393687 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:6393687 | pubmed:dateCreated | 1985-2-14 | lld:pubmed |
| pubmed-article:6393687 | pubmed:abstractText | Twenty-four patients--all primigravidae with an especially narrow, rigid cervix--were given PGE2 tablets or placebo tablets in order to prime the cervix before first trimester termination of pregnancy. 1.5 mg PGE2 or placebo tablets were administered hourly for 12 hours on the day before vacuum aspiration. The diameter of the cervix was measured by means of a Hegar dilator prior to administering the tablets and also before the vacuum aspiration the following day. The plasma level of 15-keto-13,14-dihydro-PGF2 alpha was determined before the treatment and again before the vacuum aspiration. All the 12 patients treated with PGE2 tablets had an average change in cervix diameter of 2 mm, whereas in the placebo group the average change was 0.58 mm. | lld:pubmed |
| pubmed-article:6393687 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:keyword | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6393687 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:6393687 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6393687 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6393687 | pubmed:issn | 0001-6349 | lld:pubmed |
| pubmed-article:6393687 | pubmed:author | pubmed-author:LarssonBB | lld:pubmed |
| pubmed-article:6393687 | pubmed:author | pubmed-author:KindahlHH | lld:pubmed |
| pubmed-article:6393687 | pubmed:author | pubmed-author:OlundAA | lld:pubmed |
| pubmed-article:6393687 | pubmed:author | pubmed-author:SomellCC | lld:pubmed |
| pubmed-article:6393687 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6393687 | pubmed:volume | 63 | lld:pubmed |
| pubmed-article:6393687 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6393687 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6393687 | pubmed:pagination | 625-8 | lld:pubmed |
| pubmed-article:6393687 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:6393687 | pubmed:otherAbstract | PIP: The effect of orally given prostaglandin E2 (PGE2) on cervical dilatation was assessed by administering PGE2 tablets or placebo tablets to 24 patients prior to 1st trimester pregnancy termination in a double blind study conducted in Sweden. Various PG treatment regimes were used by previous investigators to induce dilatation of the cervix for the purpose of reducing the risk of cervical laceration or perforation during termination. In the present study 1.5 mg of oral PGE2 was administered hourly for 12 hours on the day preceding termination to 12 patients and placebos were administered in the same manner to the other 12 patients. All of the patients were primigravidae and had narrow and rigid cervices. Cervical dilatation was measured, using a Hegar dilator, just prior to PGE2 or placebo administration and, again, approximately 24 hours later, or just prior to termination by vacuum aspiration. For 10 of the patients in each treatment group, blood samples were drawn before PGE2 or placebo administration and again just prior to termination to assess any changes in the plasma level of 15-keto-13,14-dihydro-PGF2 alpha. For the remaining 2 patients in each treatment group, intrauterine pressure was assessed prior to and during PGE2 and placebo administration. For the PGE2 treatment group there was a significant increase in the mean internal diameter of the cervix from 3.42 mm +or- 0.99 mm prior to PGE2 administration to 5.42 mm +or- 0.99 mm prior to termination (p0.001). In contrast, the placebo group had a mean increase in the diameter of the cervix of only .58 mm, and this increase was not significant. There was a significant increase in the plasma level of 15-keto-13,14-dihydro-PGF2 alpha among the PGE2 treated group (p0.05). Prior to treatment the mean level for both groups was 39 pg/ml, and prior to termination it was 65 pg/ml for the PGE2 group and 40 pg/ml for the placebo group. The slight increase in the placebo group was not significant. Patients with the greatest increase in cervix dilatation appeared to have the highest 15 keto-13,14-dihydro-PGF2 levels. Possible explanations for the rise in the PGE2 treatment group were discussed. For the PGE2 treatment group, contractions with an amplitude of 10-20 mm hemoglobin, and at intervals of 1-2 minutes, were registered 3 hours after treatment. The contractions did not increase after the first 3 hours and did not cause patient discomfort. 58% of the patients had gastrointestinal side effects. These effects are common when PGE2 is administered orally or intravenously. | lld:pubmed |
| pubmed-article:6393687 | pubmed:meshHeading | pubmed-meshheading:6393687-... | lld:pubmed |
| pubmed-article:6393687 | pubmed:meshHeading | pubmed-meshheading:6393687-... | lld:pubmed |
| pubmed-article:6393687 | pubmed:meshHeading | pubmed-meshheading:6393687-... | lld:pubmed |
| pubmed-article:6393687 | pubmed:meshHeading | pubmed-meshheading:6393687-... | lld:pubmed |
| pubmed-article:6393687 | pubmed:meshHeading | pubmed-meshheading:6393687-... | lld:pubmed |
| pubmed-article:6393687 | pubmed:meshHeading | pubmed-meshheading:6393687-... | lld:pubmed |
| pubmed-article:6393687 | pubmed:meshHeading | pubmed-meshheading:6393687-... | lld:pubmed |
| pubmed-article:6393687 | pubmed:meshHeading | pubmed-meshheading:6393687-... | lld:pubmed |
| pubmed-article:6393687 | pubmed:meshHeading | pubmed-meshheading:6393687-... | lld:pubmed |
| pubmed-article:6393687 | pubmed:meshHeading | pubmed-meshheading:6393687-... | lld:pubmed |
| pubmed-article:6393687 | pubmed:meshHeading | pubmed-meshheading:6393687-... | lld:pubmed |
| pubmed-article:6393687 | pubmed:meshHeading | pubmed-meshheading:6393687-... | lld:pubmed |
| pubmed-article:6393687 | pubmed:meshHeading | pubmed-meshheading:6393687-... | lld:pubmed |
| pubmed-article:6393687 | pubmed:meshHeading | pubmed-meshheading:6393687-... | lld:pubmed |
| pubmed-article:6393687 | pubmed:meshHeading | pubmed-meshheading:6393687-... | lld:pubmed |
| pubmed-article:6393687 | pubmed:year | 1984 | lld:pubmed |
| pubmed-article:6393687 | pubmed:articleTitle | Dilatation of the cervix by oral PGE2 before first-trimester termination of pregnancy. | lld:pubmed |
| pubmed-article:6393687 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6393687 | pubmed:publicationType | Clinical Trial | lld:pubmed |
